Hosted on MSN5mon
Eli Lilly's Once-Weekly Insulin Shows Non-Inferior Blood Sugar Reduction Vs Frequently Used Daily Insulins In Long Term Trials
Thursday, Eli Lilly and Co (NYSE:LLY ... efficacy and safety of once-weekly efsitora compared to once-daily insulin glargine for 52 weeks in insulin naïve patients. The trial met its primary ...
Hosted on MSN5mon
Eli Lilly's Weekly Insulin Shot Meets Two Late-Stage Study Goals
Eli Lilly LLY announced positive topline results ... The QWINT-1 study compared efsitora to daily injections of Sanofi’s SNY Lantus (insulin glargine) for 52 weeks in T2D patients using basal ...
pharmaphorum10y
Insulin glargine biosimilar approved in Europe
Lilly and Boehringer Ingelheim have gained EU approval for their biosimilar version of Sanofi's blockbuster insulin product Lantus (insulin glargine). The Europe-wide approval is the first ever ...
pharmaphorum8d
Lilly preps for rollout of its connected diabetes system
The Tempo pen is currently compatible with three of Lilly's insulin products, including Humalog and Lyumjev, both insulin lispro-based, and insulin glargine brand Basaglar. "Despite technological ...